Attached files
| file | filename |
|---|---|
| EX-5 - OPINION - SEELOS THERAPEUTICS, INC. | exh5-1.htm |
| S-1 - S-1 - SEELOS THERAPEUTICS, INC. | s1body.htm |
EXHIBIT 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors
Seelos Therapeutics, Inc.
We consent to the use of our report dated March 17, 2020, with respect to the consolidated balance sheets of Seelos Therapeutics, Inc. as of December 31, 2019 and 2018, and the related consolidated statements of operations and comprehensive loss, stockholders' equity (deficit), and cash flows for each of the years in the two-year period ended December 31, 2019, and the related notes (collectively, the financial statements), incorporated by reference herein and to the reference to our firm under the heading "Experts" in the prospectus.
Our report dated March 17, 2020 contains an explanatory paragraph that states that Seelos Therapeutics, Inc. has suffered recurring losses from operations and has a net capital deficiency, which raise substantial doubt about its ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of that uncertainty.
/s/ KPMG LLP
Short Hills, New Jersey
November 20, 2020